|
Men (n = 257)
|
Premenopausal women (n = 59)
|
Postmenopausal women (n = 312)
|
P value*
|
---|
Age, years
|
57.6 ± 10.2§
|
47.3. ± 5.2
|
63.8 ± 8.5
|
< 0.001
|
BMI, kg/m2
|
24.8 ± 3.0
|
25.2 ± 3.6
|
25.2 ± 3.2
|
0.935
|
Waist, cm
|
85.9 ± 9.2§
|
72.9 ± 13.5
|
79.4 ± 9.0
|
< 0.001
|
Smoking, n (%)
|
88 (34.2%)§
|
4 (6.8%)
|
18 (5.8%)
|
0.765
|
Hypertension, n (%)
|
130 (50.6%)
|
13 (22.0%)
|
151 (48.4%)
|
< 0.001
|
Diabetes, n (%)
|
47 (18.3%)
|
4 (6.8%)
|
55 (17.6%)
|
0.034
|
Dyslipidemia, n (%)
|
57 (22.2%)
|
9 (15.3%)
|
73 (23.4%)
|
0.230
|
Obesity, n (%)
|
13 (5.1%)
|
6 (10.2%)
|
18 (5.8%)
|
0.224
|
Family Hx of CAD, n (%)
|
47 (18.2%)
|
6 (10.2%)
|
61 (20.7%)
|
0.096
|
Coronary angiographic finding
|
CAS, n (%)
|
134 (52.1%)§
|
10 (16.9%)
|
121 (38.8%)
|
0.001
|
Medication
|
ACEi or ARB, n (%)
|
73 (28.5%)
|
8 (13.3%)
|
84 (26.9%)
|
0.033
|
CCB, n (%)
|
79 (30.9%)
|
14 (23.3%)
|
93 (29.8%)
|
0.353
|
Beta-blocker, n (%)
|
36 (14.1%)
|
3 (5.0%)
|
46 (14.7%)
|
0.039
|
Statins, n (%)
|
38 (14.8%)
|
2 (3.3%)
|
38 (12.2%)
|
0.041
|
Anti-platelet agent, n (%)
|
68 (26.6%)§
|
18 (30.0%)
|
109 (34.9%)
|
0.552
|
Laboratory finding
|
Glucose, mg/dL
|
114.0 ± 36.2
|
127.1 ± 130.4
|
107.4 ± 23.9
|
0.347
|
Total cholesterol, mg/dL
|
179.8 ± 42.2
|
190.5 ± 40.1
|
185.8 ± 44.7
|
0.501
|
HDL, mg/dL
|
46.2 ± 30.2§
|
50.8 ± 10.8
|
52.3 ± 14.9
|
0.428
|
LDL, mg/dL
|
122.9 ± 34.0§
|
110.6 ± 33.5
|
112.0 ± 34.1
|
0.580
|
Triglyceride, mg/dL
|
169.0 ± 108.6§
|
126.8 ± 71.2
|
137.6 ± 125.8
|
0.440
|
hs-CRP, mg/dL
|
2.20 ± 4.20
|
1.16 ± 1.32
|
2.59 ± 7.30
|
0.040
|
- BMI body mass index, Hx of CAD history of coronary artery disease, CAS coronary artery stenosis, ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, WBC white blood cell, LDL low-density lipoprotein, HDL high-density lipoprotein, hs-CRP high sensitive C-reactive protein
- *Comparison between pre- and postmenopausal women
- §P value < 0.05 comparison between men and women